Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

Financial integration platform developer Flinks closed a series A round led by existing investor National Bank through its NAventures subsidiary.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

The Sompo, Relx and Fujitsu-backed big data analytics provider, valued at more than $20bn in 2015, has revealed it has confidentially filed for a public listing.

Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.

Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.

UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.

Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Accenture Ventures founder Michael Redding is leaving its parent company – consulting firm Accenture – after almost 30 years.

Colin Steen, one of Syngenta Ventures' managing directors, has departed from the unit after more than two years for a chief executive role elsewhere.